CONGRESS PRESENTATIONS
CROI 2025
San Francisco, California
March 9-12, 2025
-
ViiV-Sponsored Data
-
Cabotegravir Prevention
-
Cabotegravir Treatment
Altamirano J, et al.
Clinical Outcomes Among Virologically Suppressed Women Receiving CAB+RPV LA in the OPERA Cohort
Sax P, et al.
Outcomes on Cabotegravir + Rilpivirine in Suppressed People with HIV (PWH) in TRIO Health US Cohort
Sension M, et al.
Long-term CAB+RPV LA Effectiveness in Virologically Suppressed Individuals in the OPERA Cohort
-
Dolutegravir-based Regimens
-
Fostemsavir
-
Pipeline
Ferris R, et al.
Temsavir treatment improves the recognition of HIV-1 infected cells by broadly neutralizing antibodies (bnAbs)
Griesel R, et al.
Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor
Rogg L, et al.
Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor
Taiwo B, et al..
VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study
Wensel D, et al.
Pre-clinical evaluation of effector function-enhanced variants of N6 bnAb
-
Other Disease-Related Content
Anderson K, et al.
Hospitalization Incidence Among Young Children Living with HIV in the Western Cape, South Africa
Han WM, et al.
Cancer incidence in women with HIV in Europe and Australia: a combined D:A:D and RESPOND cohort analysis
Riebensahm C, et al.
Determinants of steatotic liver disease among people with HIV in Europe and Australia
-
-
ViiV-Supported & Collaborative Data
-
Cabotegravir Prevention
Delany-Moretlwe S, et al.
No increased risk for hypertension with CAB-LA compared to TDF/FTC for PrEP: results from HPTN 084
Delany-Moretlwe S, et al.
Performance of HIV RNA screening in the context of long-acting injectable cabotegravir in HPTN 084
Fogel JM, et al.
Use of DNA profiling to resolve discrepant HIV tests in the setting of injectable cabotegravir PrEP
Grinsztejn B, et al.
ImPrEP CAB Brasil: Enhancing PrEP Coverage with CAB-LA in Young Key Populations
Grinsztejn B, et al.
PrEP Choices Among Sexual and Gender Minorities in Brazil: the ImPrEP CAB-LA Study
Hanscom B, et al.
Estimation of prevention-effective CAB-LA concentrations among MSM/TGW in HPTN 083
Landovitz RJ, et al.
Response to HIV Treatment After Long-Acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083
Magno L, et al.
Patterns of First Choice, Switching, and Discontinuation of Oral and Injectable PrEP Among Adolescents from Sexual and Gender Minorities in Brazil
Naidoo N, et al.
Expanding the PrEP method market: Early insights from offering oral PrEP, PrEP ring, and injectable CAB PrEP for HIV prevention across five countries in Africa
Nuwagaba-Biribonwoha H, et al.
High incidence of curable sexually transmitted infections in HPTN 084: a tertiary analysis
Phillips A, et al.
Dynamic Choice HIV Prevention in the context of Injectable Cabotegravir (CAB-LA): a model-based cost-effectiveness analysis
Richer D, et al.
Depression and Suicide Risk Among Sexual and Gender Minorities: Insights from the ImPrEP CAB Brasil
Wang H, et al.
Impact of rapid long-acting prep scale-up among MSM: closing the unmet needs and towards ending HIV
Wara N, et al.
Acceptability of long-acting cabotegravir among pregnant and lactating people in South Africa
-
Cabotegravir Treatment
Archary M, et al.
Safety and Pharmacokinetics of long-acting Cabotegravir and Rilpivirine in children between 20-40kgs
Dieterich M, et al.
At Home CAB/RPV Provides Novel Approach to Achieve Viral Suppression in Adherence Challenged PWH
Rana AI, et al.
Decreasing oral induction duration in support of LAI ART use with hardly-reached populations
-
Dolutegravir-based Regimens
Bamford A, et al.
Baseline and emergent resistance profiles in the African paediatric CHAPAS-4 trial
Blomme E, et al.
Effectiveness and inflammatory markers after 144 weeks of switch to DTG/3TC in a randomized trial
Di Gregorio S, et al.
Changes in body composition in people with HIV switching to DTG/3TC or BIC/TAF/FTC
Fombellida-Lopez C, et al.
Impact of art simplification with dolutegravir and lamivudine on the HIV reservoir
Kileel EM, et al.
Risk of obesity, cardiometabolic disease and MACE after switch to an integrase inhibitor in REPRIEVE
Momper JD, et al.
PK and Safety of Chronic Dolutegravir Administration in Neonates Exposed to HIV-1 (IMPAACT 2023)
Pineda J, et al.
Switching to DTG/3TC vs. BIC/FTC/TAF and Steatotic Liver Disease: A Sub-study of PASODOBLE Trial
Puertas MC, et al.
Rapid clearance of the inducible HIV-1 reservoir after initiation of antiretroviral therapy
Ryan R, et al.
Dolutegravir-based antiretroviral therapy does not reduce plasma levonorgestrel or medroxyprogesterone acetate concentrations among contraceptive users living with HIV compared with HIV-negative controls
Salinas TRW, et al.
Immunological impact of short-term BCL-2 inhibition at ART initiation on SIV infected rhesus macaques
Singh Y, et al.
Drug interactions between dolutegravir (DTG) and escalating doses of rifampicin (RIF): DORIS study
Tiraboschi JM, et al.
Switch to DTG/3TC vs BIC/FTC/TAF (PASO-DOBLE study): Efficacy and Weight Changes by Predefined Subgroups
Wu D, et al.
Depression, Sleep, and Anxiety among pregnant and postpartum women using Dolutegravir and Efavirenz
-
Other Disease-Related Content
Bloomfield G, et al.
Heart Failure Risk and Events in People With HIV in the REPRIEVE Trial
Chan P, et al.
Increasing Methamphetamine Use and Group Sex Observed in MSM with Acute HIV Infection in Bangkok
Ditzenberger GL, et al.
Prognostic Factors of Physical Function Decline in the PREPARE Study
Erlandson KM, et al.
Frailty is Associated with Higher MACE Incidence but Does Not Appear to Modify Pitavastatin Effects
Erlandson KM, et al.
No Evidence of a Detrimental Effect of Pitavastatin on Neurocognitive Function Among People with HIV
Lu MT, et al.
Plaque, Inflammation, Subclinical Myocardial Injury and MACE in the REPRIEVE Mechanistic Substudy
Platte M, et al.
People with HIV at high cardiovascular risk were undertreated with statins
Smith ED, et al.
Time-updated win ratio aligns with primary REPRIEVE findings and suggests early pitavastatin benefit
Xiner Z, et al.
Statin Effect Heterogeneity on Plaque Volume & Composition in the REPRIEVE Mechanistic Substudy
-
Translational Medicine
Bolzenius J, et al.
People with HIV exhibit structural brain changes following infection with SARS-COV-2
Capoferri AA, et al.
Early HIV-1 genetic diversity includes CTL and drug resistance mutations
Chan P, et al.
Neuronal Injury in a Subset of Individuals during Acute HIV Infection and After Immediate Treatment
Dayananda A, et al.
Delayed HIV-1 rebound correlates with enhanced CD8 T Cell activation in human trials
dos Santos JC, et al.
Genetic regulation of immune responses to CMV in spontaneous HIV controllers
dos Santos JC, et al.
Modulation of CCR5 Expression is Critical for the Maintenance of HIV Control and Reservoir Size
Huber A, et al.
Females With HIV Favor Interferon Responses Over Inflammation Upon TLR7 Activation
Li Y, et al.
Maximizing Benefits to Participants in Analytic Treatment Interruption Studies with bnAb infusions
Navas A, et al.
Heterogeneity of PD-1 expression in People Living with HIV and its relationship with host and viral-related factors
Ocampo F, et al.
Cognitive Trajectories 1 year before and after COVID-19 in an AHI cohort
Otten T, et al.
Residual HIV viremia: association with reservoir, functional immunology and systemic inflammation
Paul R, et al.
Brain volume normalization after 96 weeks of ART started during acute HIV infection.
Rios-Vazquez V, et al.
Mitochondrial Gene Variants in VARS2 Influence HIV Reservoir and T Cells in European HIV Controllers
Rios-Vazquez V, et al.
Multi-omics Clustering Reveals Distinct HIV Reservoir Profiles in the 2000HIV Cohort
Ruijten SDE, et al.
Sex-based differences and genetic regulation of cytokine responses in people living with HIV
Sacdalan C, et al.
RV550: Safety and virological outcomes in blood and lymph nodes of N-803 with ART in acute infection
Smith G, et al.
Neutralization sensitivity of viral reservoir envelopes to broadly neutralizing antibodies VRC07-523LS and PGDM1400LS
Takata H, et al.
RV550: The effects of IL-15 super-agonist N-803 with ART in acute infection on T and NK cells
Vadaq N, et al.
ART Exposure and Accelerated Aging in PLHIV: Insights from Proteomic and Methylation Clocks
van Eekeren LE, et al.
Distinct Metabolic Perturbations Link Liver Steatosis and Incident CVD in Lean but Not Obese PLHIV
-
-
Plain Language Summaries
-
Pipeline
Griesel R, et al.
Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor
Rogg L, et al.
Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor
Taiwo B, et al.
VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study
View plain language summaries of select congress presentations. These summaries include non-technical language and are formatted to help make the information accessible to a wider audience.
-
